QuidelOrtho Corporation filed its Form 10-Q for the quarterly period ended September 27, 2026, reporting a net loss of $53.8 million for the third quarter and $238.5 million for the nine months ended on that date.

Key Highlights

  • Third-quarter revenues: Total revenues were $618.9 million for the three months ended September 27, 2026, down from $699.9 million in the same period of 2025, according to the filing.
  • Nine-month revenues: Total revenues for the nine months ended September 27, 2026 were $1,869.6 million, compared with $2,006.6 million in the prior-year period.
  • Third-quarter net loss: The company reported a net loss of $53.8 million, or $0.78 per basic and diluted share, for Q3 2026.
  • Nine-month net loss: The accumulated net loss for the nine-month period was $238.5 million, or $3.49 per basic and diluted share.
  • Asset impairment charge: The filing disclosed an asset impairment charge of $12.5 million for both the three and nine months ended September 27, 2026.
  • Total debt position: Current portion of borrowings stood at $424.4 million and long-term borrowings at $2,512.9 million as of September 27, 2026.
  • Shares outstanding: As of October 28, 2026, 68,612,588 shares of common stock were outstanding, the filing stated.

QuidelOrtho's Financial Results for the Quarter and Nine Months Ended September 27, 2026

According to the filing, QuidelOrtho Corporation (NASDAQ:QDEL) reported total revenues of $618.9 million for the three months ended September 27, 2026, a decline from $699.9 million in the comparable quarter of 2025. For the nine-month period, revenues were $1,869.6 million versus $2,006.6 million in the prior year. Cost of sales, excluding amortization of intangibles, was $329.3 million for the quarter and $1,043.3 million for the nine-month period.

The company disclosed an operating loss of $7.5 million for the third quarter and $61.1 million for the nine months ended September 27, 2026. Interest expense, net, was $55.4 million for the quarter and $161.2 million year to date, contributing to a loss before income taxes of $62.9 million for Q3 and $223.6 million for the nine-month period. Net loss attributable to the quarter was $53.8 million after a benefit from income taxes of $9.1 million. The company also recorded an asset impairment charge of $12.5 million in the quarter. By comparison, the prior-year third quarter included a goodwill impairment charge of $700.7 million and restructuring, integration and other charges of $39.6 million, which are absent from the current quarter.

On the balance sheet, total assets were $5,781.3 million as of September 27, 2026, compared with $5,769.3 million at December 28, 2025. The accumulated deficit grew to $1,234.5 million from $996.0 million at the prior fiscal year-end. Total stockholders' equity declined to $1,791.3 million from $1,920.5 million over the same period. Cash and cash equivalents were $166.4 million as of September 27, 2026.

What Was Disclosed

QuidelOrtho's 10-Q for the period ended September 27, 2026 disclosed quarterly and nine-month revenue declines, net losses, an asset impairment charge of $12.5 million, significant interest expense of $161.2 million year to date, and an accumulated deficit of $1,234.5 million on the balance sheet.